[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658391":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":33,"studyPopulation":34,"armGroups":35,"interventions":29,"overallOfficials":42,"centralContacts":54,"locations":61,"responsibleParty":94,"collaborators":96,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":29,"enrollmentInfo":109,"targetDuration":29,"studyType":112,"phases":29,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":123,"whyStopped":29,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":29},[9],{"measure":10,"description":11,"timeFrame":12},"Endogenous thrombin potential (ETP)","Thrombin generation profiles will be assessed in whole blood, plasma, and platelet-rich plasma. Endogenous thrombin potential will be compared between patients with sickle cell disease and an SS genotype and patients with sickle cell disease and an SC genotype","At baseline",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Lag time of thrombin generation","Thrombin generation will be assessed in whole blood, plasma, and platelet-rich plasma. Lag time will be compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.",{"measure":18,"description":19,"timeFrame":12},"Time to peak thrombin generation","Thrombin generation will be assessed in whole blood, plasma, and platelet-rich plasma. Time to peak will be compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.",{"measure":21,"description":22,"timeFrame":12},"Peak height of thrombin generation","Thrombin generation will be assessed in whole blood, plasma, and platelet-rich plasma. Peak height will be compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.",{"measure":24,"description":25,"timeFrame":12},"Platelet activation profile","Platelet activation profiles will be assessed and compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.",{"measure":27,"description":28,"timeFrame":12},"Platelet aggregation profile","Platelet aggregation profiles will be assessed and compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.",null,{"allocation":29,"interventionModel":29,"interventionModelDescription":29,"primaryPurpose":29,"observationalModel":31,"timePerspective":32,"maskingInfo":29},"COHORT","CROSS_SECTIONAL","Sickle cell anemia is the most common genetic disease worldwide. It is due to a homozygous mutation in the beta globin gene leading to the production of abnormal hemoglobin S (HbS). This hemoglobin polymerizes and precipitates in the red blood cells (RBCs) under hypoxic conditions, leading to the rigidification of the red blood cells that obstruct the small vessels and are subsequently destroyed. The disease is thus characterized by chronic hemolytic anemia associated with painful vaso-occlusive crises (VOC) and chronic inflammation. The HbSC genotype is associated with anemia and less severe clinical manifestations than the HbSS genotype. However, the risk of venous thromboembolic events, particularly pulmonary embolism, is paradoxically higher. The pathophysiological mechanisms involved in the occurrence of VOC and venous thromboembolic events (VTE) have not been fully elucidated. They involve phenomena of ischemia-reperfusion and complex interactions between the RBC, the endothelium, the leucocytes and the platelets. The sickle RBCs express phosphatidylserine (PS) on their surface, which facilitates their adhesion to other blood cells and their interaction with the endothelium. The release of hemoglobin and free heme into the circulation, along with oxidative stress, induces endothelial activation and dysfunction, as well as vascular inflammation, platelet activation and clotting. Numerous studies have documented the existence of coagulation activation in sickle cell patients during the stable phase of the disease and during VOCs, decreased levels of physiological inhibitors of coagulation and resistance to activated protein C. One of the main mechanisms of coagulation activation in sickle cell patients is increased tissue factor expression on the surface of activated monocytes and endothelial cells. Free heme promotes NETs (neutrophil extracellular traps) formation, which activates the intrinsic coagulation pathway. Moreover, platelets probably play a pivotal role in the thrombo-inflammatory process, coagulation activation, and the occurrence of VOC and VTE. We hypothesize that sickle cell patients may exhibit a different thrombin generation profile as well as distinct platelet activation and reactivity profiles, depending on their SS or SC genotype.","Patients with sickle cell disease and the HbSS or HbSC genotype recruited from the participating study centers in Guadeloupe or Bobigny",[36,39],{"label":37,"type":29,"description":38,"interventionNames":29},"SS Group","Patients with sickle cell disease and an SS genotype.",{"label":40,"type":29,"description":41,"interventionNames":29},"SC Group","Patients with sickle cell disease and an SC genotype.",[43,47,51],{"name":44,"affiliation":45,"role":46},"Véronique Baccini, MD PhD","chu de la guadeloupe","STUDY_DIRECTOR",{"name":48,"affiliation":49,"role":50},"Sylvain Lejeune, MD PhD","Centre de Référence Maladies Rares Adulte de Bobigny \" Drépanocytose \u002F syndromes drépanocytaires majeurs \" de l'hôpital Avicenne","PRINCIPAL_INVESTIGATOR",{"name":52,"affiliation":53,"role":50},"Maryse ETIENNE JULAN, MD","CHU de la Guadeloupe Coordonnateur, Centre de référence des syndromes drépanocytaires majeurs, thalassémies et autres pathologies rares du globule rouge et de l'érythropoïèse",[55],{"name":56,"role":57,"phone":58,"phoneExt":59,"email":60},"mélanie petapermal, Master degree","CONTACT","0590934667","+590","melanie.petapermal@chu-guadeloupe.fr",[62,79],{"facility":63,"status":29,"city":64,"state":29,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Hôpital Avicenne","Bobigny","93000","France","FR",{"type":69,"coordinates":70},"Point",[71,72],2.45012,48.90982,{"lat":72,"lon":71},[75,77],{"name":48,"role":57,"phone":29,"phoneExt":29,"email":76},"sylvain.le-jeune@aphp.fr",{"name":78,"role":50,"phone":29,"phoneExt":29,"email":29},"sylvain lejeune, MD PhD",{"facility":80,"status":29,"city":81,"state":29,"zip":82,"country":83,"countryCode":29,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"CHU de la Guadeloupe","Les Abymes","97159","Guadeloupe",{"type":69,"coordinates":85},[86,87],-61.50507,16.273,{"lat":87,"lon":86},[90,92,93],{"name":91,"role":57,"phone":58,"phoneExt":29,"email":60},"mélanie petapermal",{"name":29,"role":57,"phone":29,"phoneExt":29,"email":60},{"name":52,"role":50,"phone":29,"phoneExt":29,"email":29},{"type":95,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[97],{"name":98,"class":6},"Hospital Avicenne","100658391","comparison-of-thrombin-generation-platelet-activation-and-aggregation-profiles-in-patients-with-sickle-cell-disease-depending-on-their-ss-or-sc-genotype-drepagreg-100658391",false,"NCT07852442","Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)","Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype","DrepAgreg","Inclusion Criteria:\n\n* SCD patients with SS or SC\n* diagnosis of SCD performed by electrophoresis or high-performance liquid chromatography (HPLC) in a reference laboratory for hemoglobinopathies\n* patients older than 18 years at inclusion\n* clinically in a steady state at inclusion (no complication in the last month and no transfusion in the three last months)\n* patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre) or at the Adult Rare Diseases Reference Center \"Sickle Cell Disease \u002F Major Sickle Cell Syndromes\" of the Avicenne hospital in Bobigny.\n* patients who will provide written informed consent in accordance with the Declaration of Helsinki\n* patients affiliated with national social security\n\nExclusion Criteria:\n\n* patients younger than 18 years old\n* patients with hemoglobinopathy other than SS and SC SCD\n* patients who have received transfusion therapy or on bleeding therapy for less than three months\n* patients no affiliated with national social security\n* pregnant or breastfeeding patients","ALL","18 Years",{"count":110,"type":111},60,"ESTIMATED","OBSERVATIONAL","Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation. Activated platelets from SCD patients contribute to both chronic inflammation and painful VOC. Individuals with the HbSC genotype experience anemia and less severe clinical manifestations than those with the HbSS genotype; however, they are at higher risk of venous thromboembolic events, particularly pulmonary embolism.\n\nThis study aims to investigate whether sickle cell patients exhibit different thrombin generation profiles as well as distinct platelet activation and aggregation profiles, depending on their SS or SC genotype.",[115,116],"Sickle Cell Disease","Venous Thromboembolism",[118,119,120,121,122],"Sickle cell disease","thrombin generation","platelet activation","aggregometry","platelets","NOT_YET_RECRUITING","2026-09-25",{"date":126,"type":127},"2026-10-01","ACTUAL",{"date":129,"type":111},"2026-10-15",{"date":131,"type":111},"2028-10-15",{"name":5,"class":6},2]